BioSpace News Archive

Pixium Vision Completes World’s First Successful Activation in Human of PRIMA Bionic Vision System

Pixium Vision announces today the world’s first successful human implantation and activation of PRIMA, its new generation miniaturized wireless photovoltaic sub-retinal implant, in a patient with severe vision loss from atrophic dry Age-related Macular Degeneration (AMD).

January 25, 2018
·
6 min read
Business

BGI Increases Long-Read Sequencing Capacity With Purchase of 10 PacBio Sequel Systems

This will significantly expand the capacity for Single Molecule, Real-Time Sequencing for BGI’s global sequencing service business, which currently operates two Sequel Systems and a PacBio RS II Sequencing System.

January 25, 2018
·
4 min read
Business

Meridian Bioscience Reports First Quarter 2018 Operating Results, Declares Regular First Quarter Cash Dividend, and Reaffirms Fiscal 2018 Guidance

The company reported first quarter net revenues of $52.3 million, an increase of 12% from the same period of the prior fiscal year.

January 25, 2018
·
17 min read
Drug Development

Summit Therapeutics plc : Interim 24-Week Data From PhaseOut DMD

PhaseOut DMD is evaluating the utrophin modulator ezutromid in patients with Duchenne muscular dystrophy.

January 25, 2018
·
11 min read
Drug Development

Juntendo University Research: Cognitive Neuroscience: the Awareness of Ignorance

Monkeys were presented with a metacognition task composed of a memory and a bet stage.

January 25, 2018
·
6 min read
Business

Myriad to Announce Fiscal Second-Quarter 2018 Financial Results on February 6, 2018

During the call, Mark C. Capone, president and CEO and Bryan Riggsbee, CFO, will provide an overview of Myriad’s financial performance for the fiscal second-quarter and provide a business update.

January 25, 2018
·
2 min read
Pharm Country

Athenex Announces Pricing of Offering of Common Stock

In addition, Athenex has granted the underwriters a 30-day option to purchase up to an additional 645,000 shares of common stock at the same price.

January 25, 2018
·
3 min read
Drug Development

Ezutromid Significantly Reduced Muscle Damage in DMD Patients in 24-Week Interim Data From Summit’s PhaseOut DMD Clinical Trial

PhaseOut DMD is evaluating the utrophin modulator ezutromid in patients with Duchenne muscular dystrophy (‘DMD’). The focus of the planned interim analysis was on biopsy measures that show:

January 25, 2018
·
11 min read
Business

NeuroMetrix Reports Q4 and Full Year 2017 Financial Results

The Company develops and markets novel therapies, based on neurostimulation and digital medicine, for chronic health conditions.

January 25, 2018
·
6 min read
Deals

Bay Area’s Menlo Therapeutics Prices IPO at $17 Per Share

The offering is expected to close on January 29, 2018, subject to customary closing conditions.

January 25, 2018
·
2 min read